Supporting our findings, PR-B promoter was previously found to be methylated in endometrial carcinoma [62] and the loss of expression was referred to as an independent prognostic factor for cause-specific survival in high risk patients [63]. This evidence concerns the gene RB1 and endometrial carcinoma.